Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: A prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

Journal of Clinical Oncology

Volumn 22, Issue 7, 2004, Pages 1188-1194

  Kirchner, H ^b   Jonas, U ^b   Bergmann, L ^b   Schott, H ^b   Heynemann, H ^b   Fornara, P ^b   Loening, S A ^b   Roigas, J ^b   Muller S C ^b   Bodenstein, H ^b   Pomer, S ^b   Metzner, B ^b   Rebmann, U ^b   Oberneder, R ^b   Siebels, M ^b   Wandert, T ^b   Puchberger, T ^b   Reitz, M ^b   Atzpodien, Jens ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; FLUOROURACIL; INTERLEUKIN 2; ISOTRETINOIN; VINBLASTINE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ADULT; AGED; DISEASE FREE SURVIVAL; FEMALE; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TUMOR; MALE; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; INTERLEUKIN-2; ISOTRETINOIN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 2142695181     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.06.155     Document Type: Article

References (21)

1. Elson PJ, Witte RS, Trump DL: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48:7310, 1988
2. Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889, 1987
3. Atzpodien J, Korfer A, Franks CR, et al: Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet 335:1509-1512, 1990
4. Sleijfer DT, Janssen RA, Buter J, et al:. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 10:1119-1123, 1992
5. Jayson GC, Middleton M, Lee SM, et al: A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer. Br J Cancer 78:366-369, 1998
6. Lissoni P, Barni S, Ardizzoia A, et al: Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha. Eur J Cancer 28:92-96, 1992
7. Savage PD, Muss HB: Renal Cell Cancer, in Devita VT, Hellman S, and Rosenberg SA (eds): Biologic Therapy of Cancer. Philadelphia, PA, Lippincott Williams and Wilkins, 1995, pp 373-387
8. van Herpen CM, Jansen RL, Kruit WH, et al: Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: A multicenter phase II study-Dutch Immunotherapy Working Party. Br J Cancer 82:772-776, 2000
9. Atzpodien J, Kirchner H, Illiger HJ, et al: IL-2 in combination with IFN-α and FU versus tamoxifen in metastatic renal cell carcinoma: Long-term results of a controlled randomized clinical trial. Br J Cancer 85:1130-1136, 2001
10. Fossa SD, Martinelli G, Otto U, et al: Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: Results of a European multi-center phase III study. Ann Oncol 3:301-305, 1992
11. Pectasides D, Varthalitis J, Kostopoulou M, et al: An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer. Oncology 55:10-15, 1998
12. Stadler WM, Kuzel T, Dumas M, et al: Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol 16:1820-1825, 1998
13. Motzer RJ, Schwartz L, Law TM, et al: Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: Antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 13:1950-1957, 1995
14. Lopez-Hänninen EH, Kirchner H, Atzpodien J: Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients. J Urol 155:19-25, 1996
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
16. Joffe JK, Patel PM, Banks RE, et al: Cytokines in combination with chemotherapy for advanced renal carcinoma: The importance of patient selection. Cancer Biother Radiopharm 11: 09-313, 1996
17. Atzpodien J, Kirchner H, Duensing S, et al: Biochemotherapy of advanced metastatic renal-cell carcinoma: Results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. World J Urol 13:174-177, 1995
18. Motzer RJ, Murphy BA, Bacik J, et al: Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18:2972-2980, 2000
19. Atzpodien J, Royston P, Reitz M: Metastatic Renal Carcinoma Extended Staging System. Br J Cancer 88:348-353, 2003
20. Negrier S, Escudier B, Lasset C, et al: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma-Groupe Francais d'Immunotherapie. N Engl J Med 338:1272-1278, 1998
21. Yang JC, Rosenberg SA: An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am 1:S79-S84, 1997 (suppl 3)